Now Reading: Gland Pharma shares surge 4% on US FDA nod for Sugammadex injection
-
01
Gland Pharma shares surge 4% on US FDA nod for Sugammadex injection
Gland Pharma shares surge 4% on US FDA nod for Sugammadex injection
Shares of Gland Pharma rose over 4% on Tuesday after the Hyderabad-based drugmaker received US FDA approval for its generic version of Sugammadex injection, used to reverse the effects of certain muscle…
The Story in Brief
Shares of Gland Pharma rose over 4% on Tuesday after the Hyderabad-based drugmaker received US FDA approval for its generic version of Sugammadex injection, used to reverse the effects of certain muscle relaxants during surgery. The approval covers 200 mg/2 mL and 500 mg/5 mL single-dose vials.
The company stated its product is bioequivalent and therapeutically equivalent to Merck Sharp & Dohme's Bridion. Gland Pharma launched the product immediately through a marketing partner. Citing IQVIA data, the firm noted that the branded product recorded US sales of approximately $1.6 billion in the 12 months ending April 2026.
The Indian Opinion
Market analysts and some media outlets are framing this as a 'blockbuster' event, but the real test lies in whether Gland Pharma can capture significant market share from the reference product's established dominance. The $1.6 billion US sales figure cited by the company is for the entire category, not just its own product; the actual revenue it generates will depend on pricing and volume. Will the company disclose first-quarter sales figures for this launch to justify the stock's reaction?
Source: thehindu.com
This story was synthesised by AI from the source linked above.
